Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib. - Wikidata - thesis-toulmin - TriplyDB

Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib.

Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib.

http://www.wikidata.org/entity/Q34468729

about

Progress in systemic therapy of advanced hepatocellular carcinoma Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives Systemic treatment of hepatocellular carcinoma: Past, present and future Lenvatinib and Palbociclib.New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions.Lenvatinib: first global approval.Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses.Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy.Clinical Pharmacology Tools and Evaluations to Facilitate Comprehensive Dose Finding in Oncology: A Continuous Risk-Benefit Approach.Clinical Pharmacokinetic and Pharmacodynamic Profile of Lenvatinib, an Orally Active, Small-Molecule, Multitargeted Tyrosine Kinase Inhibitor.Early prediction of lenvatinib treatment efficacy by using F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma that is refractory to radioiodine treatment: a protocol for a non-randomized single-arm multicenter observational stud Angiogenesis: Managing the Culprits behind Tumorigenesis and Metastasis

P2860

Q26740217-CC220310-8507-4611-8DF9-42F741FE18E9 Q26751274-8663EE35-A84D-4883-BDF8-A801631771B3 Q33854034-E376AD4B-4698-4EEE-8B21-ADA70D905F0D Q36109982-DE6C82B1-4A6B-46AA-9065-6A878D414A67 Q38282800-F59B4383-CAA0-4965-A988-98A0EB19A06D Q38385844-BEFBA96B-CB8A-484B-8459-9BA5EA699C12 Q38754388-F3D12CD1-7C50-4167-A8CE-B10CE2080AE9 Q42053469-4A27328A-33B8-47F3-B22B-B5DCBD49A40C Q47969034-36D1F4AE-E3D1-4CAF-AE3E-A28AE8AD6409 Q53520555-ECAFF457-2160-447E-809B-3A126CAE5CB0 Q56515680-F93C1D85-C6C0-42E1-BCA2-C141305A60FF Q57825996-40318589-1F63-4AEE-BA16-37AA610E6531

P2860

Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib.

http://www.wikidata.org/entity/Q34468729

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Pharmacodynamic change in plas ...... i-kinase inhibitor lenvatinib.

@ast

Pharmacodynamic change in plas ...... i-kinase inhibitor lenvatinib.

@en

Pharmacodynamic change in plas ...... i-kinase inhibitor lenvatinib.

@nl

type

label

Pharmacodynamic change in plas ...... i-kinase inhibitor lenvatinib.

@ast

Pharmacodynamic change in plas ...... i-kinase inhibitor lenvatinib.

@en

Pharmacodynamic change in plas ...... i-kinase inhibitor lenvatinib.

@nl

prefLabel

Pharmacodynamic change in plas ...... i-kinase inhibitor lenvatinib.

@ast

Pharmacodynamic change in plas ...... i-kinase inhibitor lenvatinib.

@en

Pharmacodynamic change in plas ...... i-kinase inhibitor lenvatinib.

@nl

P1433

Q34468729-427A2F27-A829-49F1-81A1-05AAB1F18598

P1476

Q34468729-1C28D676-1CF0-4508-9AF9-D80139AD1C45

P2093

Q34468729-32A278B9-2FE9-469A-8AED-1053EDC3B380

Q34468729-541C6D6D-95C6-4279-B28B-6123C5781A70

Q34468729-5F8EACB5-2138-47D3-9FB7-1B3C48582084

Q34468729-6E1760C4-2A0D-431D-909A-B37BAEF7D545

Q34468729-8353807B-997B-4D59-AAD6-FEC9ADDF71EB

Q34468729-8FB22E8F-8EC6-4ECD-853D-CA950AE685B8

Q34468729-907E5E49-7DFE-4D20-AF9B-00F04A97A059

Q34468729-B6471F62-2B92-4F0F-AF5E-322C27A8A458

Q34468729-CF2FB64B-3A9C-4151-9CAE-863D82A82F3F

Q34468729-F20AC754-93D7-45AB-8D9E-1997C0B3D242

P2860

Q34468729-0C61FB74-658C-4ADD-954C-B4C4BF0D2BE4

Q34468729-0CA90E71-4F28-4162-8A59-BC4613E11547

Q34468729-1184A5B9-F20A-4F8F-A345-ED9CAEBD6B93

Q34468729-1CCEC913-E0BB-413F-A53D-773B22149147

Q34468729-1CEED893-6388-4E8B-B848-8EFA046DBFC4

Q34468729-27E79152-A916-4745-A745-0BF1DE3052D3

Q34468729-29CBD126-5294-45D3-8D23-FD1E1125D6AD

Q34468729-41CF032C-975E-4B92-B760-D224BB307221

Q34468729-449A3BB8-6EA9-416D-B826-2DDA2E43BC48

Q34468729-44D2C611-DA47-404A-B9F9-D1D1999F9C4A

P2888

Q34468729-1960A6E5-10AF-4E6F-B8FF-269D9347421F

P304

Q34468729-7BE9806F-CE46-4856-94CF-A290B3D75859

P31

Q34468729-D9FDDF3E-3C86-4DC4-88A2-79FBF4A8F544

P356

Q34468729-50CBEC18-B7C9-4FC0-AD04-4DFDBA0142A6

P407

Q34468729-18AC1566-E936-41C2-A443-865D1B2FF727

P478

Q34468729-6D916922-2D77-4488-AAC8-D760AD9AA228

P577

Q34468729-97774D80-AEF3-4840-87B4-ABACA1194BD3

P5875

Q34468729-D93C6F57-FE98-4E31-8D4F-8548FD6AE7E8

P6179

Q34468729-5955F6D2-9A94-494B-832D-688C6992DE3A

P698

Q34468729-D0500D47-B27D-405A-A430-DAA87FC7119D

P932

Q34468729-A7A2F8F6-C645-4E01-963D-42359C0CAD39

P356

1471-2407-14-530

P1433

P1476

Pharmacodynamic change in plas ...... i-kinase inhibitor lenvatinib.

@en

P2093

Fumiaki Koizumi

http://www.w3.org/2001/XMLSchema#string

Hiroshi Nokihara

http://www.w3.org/2001/XMLSchema#string

Kazuto Nishio

http://www.w3.org/2001/XMLSchema#string

Kenichi Saito

http://www.w3.org/2001/XMLSchema#string

Noboru Yamamoto

http://www.w3.org/2001/XMLSchema#string

Noriyuki Koyama

http://www.w3.org/2001/XMLSchema#string

Tomohide Tamura

http://www.w3.org/2001/XMLSchema#string

Wataru Yusa

http://www.w3.org/2001/XMLSchema#string

Yasuhide Yamada

http://www.w3.org/2001/XMLSchema#string

Yuki Nishioka

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical biomarkers of response in advanced renal cell carcinoma

The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Intronic polyadenylation signal sequences and alternate splicing generate human soluble Flt1 variants and regulate the abundance of soluble Flt1 in the placenta.

Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors.

Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer.

Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor.

Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth.

Vascular endothelial growth factor and the regulation of angiogenesis.

P2888

1471-2407-14-530

P304

530

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-14-530

http://www.w3.org/2001/XMLSchema#string

P407

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2014-07-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264127042

http://www.w3.org/2001/XMLSchema#string

P6179

1037421023

http://www.w3.org/2001/XMLSchema#string

P698

25047123

http://www.w3.org/2001/XMLSchema#string

P932

4223557

http://www.w3.org/2001/XMLSchema#string